Marwan Fakih: The future of IO will get the cures to MSS CRC
Marwan Fakih, Associate Director for Clinical Sciences at City of Hope, shared on LinkedIn:
“A milestone presentation today at GI ASCO. I have been preaching the value of IO in MSS non-liver mets, particularly with CTLA-4 / PD-1 inhibition for the last 5 years, for the sake of our patients. Happy to see this Randomized Phase 2 through and to present the data at GI ASCO today. The durability of responses with BOT/BAL and clear contribution of components will hopefully set the stage for definitive phase 3 trials that bring these options to our patients.
10 years ago, we used to say cure is impossible with systemic therapy in CRC. Fast forward, everyone believes IO cures a large number of MSI high but NOT MSS. I dare say that the future of IO will get the cures to MSS CRC. Indeed, I am already seeing those IO treated patients with protracted remissions in my clinic.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023